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Abstract 
Flavonoids are bioactive compounds that are known to be neuroprotective against 
glutamate-mediated excitotoxicity, one of the major causes of neurodegeneration. 
The mechanisms underlying these effects are unresolved, but recent evidence 
indicates flavonoids may modulate estrogen signaling, which can delay the onset 
and ameliorate the severity of neurodegenerative disorders. Furthermore, the roles 
played by glial cells in the neuroprotective effects of flavonoids are poorly 
understood. The aim of this study was to investigate the effects of the flavonoid 
agathisflavone (FAB) in primary neuron-glial co-cultures from postnatal rat cerebral 
cortex. Compared to controls, treatment with FAB significantly increased the number 
of neuronal progenitors and mature neurons, without increasing astrocytes or 
microglia. These pro-neuronal effects of FAB were suppressed by antagonists of 
estrogen receptors (ERα and ERβ). In addition, treatment with FAB significantly 
reduced cell death induced by glutamate and this was associated with reduced 
expression levels of pro-inflammatory (M1) microglial cytokines, including TNFα, 
IL1β and IL6, which are associated with neurotoxicity, and increased expression of 
IL10 and Arginase 1, which are associated with anti-inflammatory (M2) 
neuroprotective microglia. We also observed that FAB increased neuroprotective 
trophic factors, such as BDNF, NGF, NT4 and GDNF. The neuroprotective effects of 
FAB were also associated with increased expression of glutamate regulatory 
proteins in astrocytes, namely glutamine synthetase (GS) and Excitatory Amino Acid 
Transporter 1 (EAAT1). These findings indicate that FAB acting via estrogen 
signaling stimulates production of neurons in vitro and enhances the neuroprotective 
properties of microglia and astrocytes to significantly ameliorate glutamate-mediated 
neurotoxicity.  
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Introduction 
 
With the increase in life expectancy over the last century, the prevalence of 
age-related disorders, such as neurodegenerative diseases continues to rise. This is 
the case of Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's 
disease (HD) and other neurodegenerative diseases (Procaccini et al., 2016). In 
addition, ischemic stroke is one of the main causes of death in the world and occurs 
due to the significant decrease or occlusion of blood flow in a particular brain area, 
which may be temporary or permanent (Jean et al., 2012). A key cause of neuronal 
loss is glutamate-mediated excitotoxicity, which is known to be involved in the 
pathogenesis of AD, HD, PD and ischemic stroke (Xu et al., 2016, Pallo et al., 2016, 
Douaud et al., 2009, Xing et al., 2012). Glutamate is the main excitatory 
neurotransmitter in the central nervous system (CNS), but elevated levels of 
glutamate result in neuronal excitotoxicity (Olney, 1969). Astrocytes are responsible 
for the removal and recycling of extracellular glutamate via the glutamate transporter 
EAAT1 and glutamine synthetase (GS) (Hertz, 2014). This is essential to maintain 
spatial and temporal resolution of synaptic signaling and to prevent excitotoxicity 
(Danbolt, 2001, Meeker et al., 2015). Hence, astroglial glutamate regulation is a 
potential therapeutic target in multiple neuropathologies. Furthermore, oxidative 
stress and neuroinflammation have been implicated in the progression of AD, HD, 
PD and ischemic stroke (Agostinho et al., 2010, Amor et al., 2010, Uttara et al., 
2009, Chen et al., 2016, Xing et al., 2012). Neuroinflammation constitutes a 
beneficial process involved in the maintenance of organ homeostasis and the brain 
response to infection or injury (Glass et al., 2010). However, sustained 
neuroinflammatory processes contribute to the cascade of events leading to the 
progressive neuronal damage observed in ageing (Barrientos et al., 2015). In this 
context, as the resident immune cells of the brain, microglia is central to 
neuroinflammation and controlling their responses is relevant to most 
neuropathologies (Salter and Stevens, 2017).  
 
Flavonoids are polyphenolic compounds that are ubiquitously present in plants and 
have biological effects on animal cells (Pandey and Rizvi, 2009). Plants containing 
these bioactive compounds have been used for centuries because of their beneficial 
4 
 
effects on human health, reducing inflammation, promoting cognition and preventing 
cancer (Scalbert et al., 2005, Spencer et al., 2008, Williams and Spencer, 2012, 
Spencer et al., 2012, Sokolov et al., 2013, Busch et al., 2015). Moreover, dietary 
flavonoids can be neuroprotective and anti-inflammatory and successfully reduce the 
risk or delay the onset or progression of AD (Dai et al., 2006). The effects of 
flavonoids are generally related to their antioxidant properties and modulation of 
intracellular signaling pathways, such as ERK1–ERK2 and PI3K neuroprotective 
signalling. In addition, flavonoids may act via estrogen signaling (Lehart et al., 2005), 
although at present this is poorly defined in neuropathology. Nonetheless, estrogen 
has been shown to affect neural development, maturation, function, and plasticity, in 
particular influencing synaptogenesis, being anti- apoptotic (Brinton, 2013, Sehara et 
al., 2013) and stimulating neurite outgrowth (Rozovsky et al., 2002, Islamov et al., 
2002). Estrogens induce their effects through estrogen receptors (ER), which exist 
mainly as ERα and ERβ forms. In particular, it has been discovered that ERs 
coordinate multiple neuroprotective signaling cascades, either directly or through 
interactions of ERs with the receptors for other neuroprotective factors (Arevalo et 
al., 2015). For example, studies on primary cortical neurons have shown that the 
synthetic estrogen estradiol activates ERK1–ERK2 and PI3K neuroprotective signal-
ling in parallel in the same neurons (Mannella and Brinton, 2006).  
Notably, estradiol is used therapeutically in humans, but its therapeutic use in 
controlling neurodegeneration is limited because of the increased risk of some 
estrogen-dependent cancers. Therefore, the role of ERs in the activation of 
neuroprotective mechanisms has led researchers to assess the neuroprotective 
potency of different ER ligands, such as selective ER modulators (SERMs) (Arevalo 
et al., 2015). The possibility that flavonoids can act as SERMs represents a potential 
alternative to estrogen that avoids its side-effects for the treatment or the prevention 
of neurodegeneration, since these compounds may activate multiple neuroprotective 
mechanisms of action. Here, we have investigated the neuroprotective and anti-
inflammatory effect of agathisflavone a biflavonoid extracted from Poincianella 
pyramidalis (Tul.), an abundant plant at the northeast of Brazil, in primary cultures of 
neurons and glial cells. The results indicate agathisflavone acts as an SERM to 
promote generation of neurons in vitro and is a potent neuroprotective agent against 
glutamate-mediated excitoxicity, acting at least in part by polarizing microglia 
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towards an anti-inflammatory and neuroprotective M2 phenotype and enhancing 
glutamate regulation in astrocytes. 
 
Methods 
 
Neuron/Glial cell primary co-cultures 
Cell cultures were prepared from cerebral hemispheres from Wistar rats, 
obtained from the Department of Physiology of the Institute of Health Sciences of the 
Federal University of Bahia (Salvador, BA, Brazil). All experiments were performed in 
accordance with the local Ethical Committee for Animal Experimentation of the 
Health Sciences Institute (protocol nº027/2012). 
Glial cell primary cultures were obtained from cerebral hemispheres of Wistar 
rats as previously described (Silva et al., 2013). Cerebral hemispheres from one-
day-old postnatal Wistar rat pups were isolated aseptically, and the meninges were 
mechanically removed. The cerebral cortex was dissected out and then gently forced 
through a sterile 70-µm Falcon™ Cell Strainer. Cells were suspended in DMEM 
HAM F12 medium (Gibco®), supplemented with 2 mM L-glutamine, 0.011 g/l 
pyruvate, 10% FBS, 3.6 g/L Hepes,  33 mM glucose (Cultilab, SP, Brazil), 100 IU/mL 
penicillin G and100 µg/ml streptomycin, and cultured in 100mm Ø plates in a 
humidified atmosphere with 5% CO2 at 37°C. Culture medium was changed every 
two days, and cells were cultured for 15 days (Fig. 1A). Cells were then washed 3X 
with PBS, detached with trypsin (Trypsin EDTA) and plated at a density of 1x105 
cell/cm2 and maintained in culture for 48 h. After incubation, neurons obtained from 
cerebral hemispheres of 15 day-old Wistar rat embryos, using the same method 
described above for glial isolation, were suspended in supplemented DMEM/HAM 
F12 and seeded at half the amount of glial cells (5x104 cells/cm2) onto the astroglial 
monolayer. Cells were incubated in a humidified atmosphere with 5% CO2 at 37°C 
for 8 days, when treatments were performed. 
 
Microglial Cultures 
Microglial cultures were obtained from the cerebral cortex of new born Wistar 
rats as described previously (Mecha et al., 2011). The brain meninges were carefully 
stripped off, and cerebral tissues were washed in PBS with 0.6 % glucose (Sigma 
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Aldrich, St. Louis, MO, USA), dissociated mechanically and resuspended in DMEM 
(Cultilab, SP, Brazil), supplemented with 10% FBS (Gibco®), 10% HS, 4 mM L-
glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin.  The cells were 
cultured on poly-D-lysine (25 µg/mL)-coated flasks. The cultures were incubated at 
37°C in humidified 5% CO2upon reaching confluence (7-10 days). The microglia 
were isolated from astrocytes at 13 DIV by shaking for 3 h at 37°C at 165 rpm. 
Isolated microglia were seeded at a density of 3x104/cm2, and experiments 
performed after 24 h. For LPS and IL4 treatment, microglial cells were incubated for 
an additional 24 h with DMEM medium without FBS (control), with LPS (1 μg/mL, 
Sigma Aldrich, St. Louis, MO, USA) and IL4 (20ng/mL, Sigma Aldrich, St. Louis, MO, 
USA). 
 
Treatments 
Agathisflavone was extracted from Poincianella pyramidalis (Tul.) leaves as 
previously described (Mendes et al., 2000), stored at 100 mM in dimethyl sulfoxide 
(DMSO; Sigma Chemical Co), and kept out of light at -20oC until use. 17β-estradiol 
(EST, the primary estrogen hormone) was obtained from Tocris (2824) stored at 100 
mM in dimethyl sulfoxide (DMSO; Sigma Chemical Co), and kept out of light at -20oC 
until use. 
To determine the effects of agathisflavone on neuronal and neuronal 
progenitor number, neuron-glial co-cultures were treated for 72 h with10 µM of 
agathisflavone, diluted in culture medium; control cultures were treated with DMSO 
the vehicle of dilution of FAB (Fig. 1A). 
To induce excitotoxicity, co-cultures were treated with 1 mM glutamate (Glut; 
Sigma Chemical Co) for 4 h, then the medium was removed and replaced with 
medium containing agathisflavone (0.1-10 µM), 17β-estradiol (100 nM) or vehicle. 
The experiments were performed after 24 h and 72 h after treatment (Fig. 1B). 
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Fig.1. Experimental design. (A) Co-cultures of neuron and glial cells were obtained from cerebral 
hemispheres from Wistar rats. Co-cultures were treated with agathisflavone (FAB, 10 µM) for 72 h 
when the analyses for neurogenesis were performed. (B) Excitotoxicity: Co-cultures of neuron and 
glial cells were pretreated with 1mM of glutamate for 4 h, after glutamate treatment cells were treated 
with FAB (0.1-10 µM) or 17β Estradiol (100 nM) for 24 and 72 h. 
 
ER Antagonists Treatments 
To establish if the effects of agathisflavone were mediated through estrogen 
receptors (ER), neuron-glial co-cultures were treated with specific ER antagonists 
starting 2 h before agathisflavone treatment through 72 h (during FAB treatment). In 
this study, we used selective antagonists for ER-α 1,3-Bis(4-hydroxyphenyl)-4-
methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP 
dihydrochloride; 10 nM, from Sigma), or for ER-β 4-[2-Phenyl-5,7-bis(trifluoromethyl) 
pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) at 1 μM (Tocris). Control cells were 
treated with the vehicle of dilution of agathisflavone (DMSO). 
 
Immunostaining 
For immunostaining, cells were washed with phosphate-buffered saline (PBS) 
three times and fixed with 4% paraformaldehyde for 15 min at room temperature 
(RT). Cultures were washed three times with PBS, incubated with 0.3% Triton X-100 
in PBS (Sigma) for 5 min and blocked by incubation with PBS containing 5% bovine 
serum albumin (BSA) (Sigma) for 1 h. After blocking, samples were incubated with 
primary antibodies diluted in PBS containing 1% of BSA overnight. Cells were 
washed with PBS three times. Then, secondary antibodies were added to cells and 
incubated for 2 h. The cells were washed with PBS three more times and incubated 
8 
 
with 1.0 μg/mL 4,6-diamidino-2-phenylindole (DAPI) for nuclear staining. Staining 
was visualized on a confocal microscope (Leica, TCS-SP5). Images were captured 
with either a 40×objective or a 63×oil immersion objective. The following primary 
antibodies were used at the indicated dilutions: anti-Tubulin β3 (mouse, 1:1000; 
BioLegend, 801201), anti-doublecortin (rabbit, 1:1000; Abcam, ab18723), anti-MAP2 
(Mouse, 1:500; Sigma, M1406), anti-neurofilament (mouse, 1:400; Abcam, 
AB24574), anti-vGlut2 (mouse, 1:500; Abcam, AB79157), anti-GFAP (rabbit, 1:300; 
DAKO, Z0334), anti-Glutamine Synthetase (GS, rabbit, 1:500; Abcam, ab49873), 
anti-EAAT1(rabbit, 1:200; Abcam, ab416), anti-Iba1 (rabbit, 1:200; Wako, 019-
19741), anti-CD11b/c [OX42] (mouse, 1:200; Abcam, ab1211), anti-CD68 (rat,1:100; 
Abcam, ab53444), anti-CD206 (mouse, 1:100; BioRad, MCA2235GA), anti-active 
caspase-3 (rabbit, 1:300; Chemicon, ab3623).The following secondary antibodies 
were used at the indicated dilutions: Alexa Fluor 488-conjugated goat anti-mouse 
IgG conjugated (1:400; Molecular Probes, A11001), Alexa Fluor 594-conjugated goat 
anti-rabbit IgG(1:400; Molecular Probes, A11037). Alexa Fluor 555-conjugated goat 
anti-rat IgG (1:400; Molecular Probes, A21434), Alexa Fluor 488-conjugated goat 
anti-rabbit IgG conjugated (1:400; Molecular Probes, A11008). All experiments 
included cultures where the primary antibodies were not added, unspecific stained 
was not observed in such negative controls. 
 
Fluoro-Jade B staining 
Fluoro-Jade B (FJ-B) stain (Schmued and Hopkins, 2000) was used to 
investigate neuronal loss. Neuron-glial co-cultures were cultivated in 96 well black 
plates, 1.5x104 cells/cm2, and were treated with 1 mM glutamate (Glut) for 4 h, then 
the medium was removed and replaced with medium contain agathisflavone or 17β-
estradiol, and kept for 72 h. After treatment, the cultures were fixed in ethanol at 4°C 
for 10 min. Cultures were washed three times with PBS then incubated with 0.3% 
Triton X-100 in PBS (Sigma) for 10 min. After washes in PBS three times, cells were 
incubated with 0.001% Fluoro-jade B in PBS for 30 min at RT, under agitation and 
protected from the light. After incubation, the cells were washed three times with 
PBS and incubated for 5 min at RT in the dark with 1.0 μg/mL 4,6-diamidino-2-
phenylindole (DAPI) for nuclear staining, and then washed 3 times with PBS. 
Analyses were performed in a spectrophotometer (Varioskan™ Flash Multimode 
Reader, Thermo Plate), and the fluorescence intensity of each sample was 
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measured at480 nm for fluoro-Jade B and 350 nm for DAPI. The values of 
absorbance of fluoro Jade B of each well were normalized to the DAPI absorbance 
in the same well. 
 
RNA extraction and qPCR 
After 24 h of treatment, cells were processed for qPCR. Total RNA was 
isolated using Trizol reagent (Ambiom™ 15596018) and subjected to DNase 
treatment using TURBO DNA-free™ Kit (Invitrogen, AM1906), following 
manufacturer’s instructions. The concentration of the RNA samples was determined 
spectrophotometrically. Complementary DNA was generated from 2.5 μg total RNA 
using the SuperScript® VILO™ Master Mix according to manufacturer 
recommendations. Expression of mRNA of target genes and the endogenous 
controls genes Actin B and HPRT1 were assessed by real-time PCR (with TaqMan 
Gene Expression Assay products, Applied Biosystems), according to the 
manufacturer’s recommendations. Expression levels for each gene of interest were 
calculated by normalizing the quantified mRNA amount to Actin b and HPRT1. 
Relative gene expression was determined and used to test significance between 
different groups. Real-time PCR was performed in QuantStudio™ 7 Flex Real-
Time PCR System (AppliedBiosystems, CA, USA) using TaqMan Universal PCR 
Master Mix II (Applied Biosystems™ 4440044), TaqMan probes and primers 
provided by Applied Biosystems. The assay ID provided by the manufacturer are the 
following: IL-1b (Rn00580432_m1), IL-6 (Rn01410330_m1), TNF (Rn01525859_g1), 
IL-10 (Rn00563409_m1), TGFB1 (Rn00572010_m1), Arg1 (Rn00691090_m1), 
BDNF (Rn02531967_s1), NGF (Rn01533872_m1), NTF4 (Rn00566076_s1), GDNF 
(Rn00569510_m1), CDNF (Rn01765001_m1), HPRT1 (Rn01527840_m1), Actin B 
(ACTB; Rn00667869_m1). 
 
Flow Cytometry Analysis 
After treatments, the cells were analyzed by flow cytometry. Cells were 
dissociated with trypsin, washed with PBS, and fixed with 4% paraformaldehyde for 
15 min. Cell permeabilization was achieved with PBS containing 0.3% Triton X-100 
for 5 min and blocking was performed in PBS with 5% BSA (Sigma). Following 3 
washes with PBS, cells were incubated overnight with anti-β-tubulin III (mouse, 
1:2000, BioLegend 801202), anti-doublecortin (rabbit, 1:2000; Abcam, ab18723), 
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anti-MAP2 (Mouse, 1:500; Sigma, M1406), anti-vGlut2 (Mouse, 1:1000; Abcam, 
AB79157),anti-GFAP (rabbit, 1:500; DAKO, Z0334), anti-Iba1(rabbit, 1:500; Wako, 
019-19741) antibodies in PBS with 1% BSA. Cells were washed with PBS three 
times and hybridized with Alexa 488- or Alexa 633-conjugated secondary antibodies 
for 2 h (1:1000; Invitrogen), after which three more PBS washes were performed. 
Flow cytometry was performed using a FACSCalibur cytometer (Beckman Coulter, 
Brea, CA). Data analyses were performed using FlowJo or WinMDI software (v.2.9). 
Fluorescence thresholds and immune positive cell rates were calculated using the 
same program. For all experiments, the isotype antibodies were used as controls.  
 
Western Blot 
After treatments, neuron-glial co-cultures were collected and lysis buffer was 
added, total protein was extracted with buffer (4M urea, 2% SDS, 2 mM EGTA, 
62,5mM Tris – HCl pH 6,8, 2 mM EDTA, 0,5% Triton X-100) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich, P8340). Thirty micrograms of protein per 
lane were electrophoretically separated on a 10% polyacrylamide gel. After 
separation, proteins were transferred into a polyvinylidenedifluoride (PVDF) 
membrane (Hybond, Amersham, Piscataway, USA) in a semi-dry system (Bio-Rad, 
Hercules, USA) for 120 min at a constant current of 0.15 mA. Membranes were 
blocked with 5% nonfat milk in tris-buffered saline containing 0.05% Tween-20 (TBS-
T) for 1 h at RT under agitation. After blocking, membranes were incubated with 
primary antibodies for either Anti-Glutamine Synthetase (GS, rabbit, 1:10000; 
Abcam, ab49873) or Anti-Cyclophilin B (Rabbit 1:5000 Abcam, ab178397) overnight 
at 4°C. Afterward, membranes were washed with TBS-T three times and incubated 
for 1 h at RT under agitation with goat anti-rabbit peroxidase-conjugated (1:10000; 
Molecular probes, G21234) secondary antibody diluted in 5% nonfat milk in TBS-T. 
Membranes were then washed three times under agitation in TBS-T. Blots were 
developed using Amersham ECL Prime (GE). After protein detection, densitometric 
analyses were performed using ImageJ software. The values of each protein were 
normalized to the Cyclophilin B amount in the same lane. 
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 5 and validated 
with Student's t-tests or one-way analysis of variance (ANOVA) when more than 2 
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groups were compared. Confidence intervals were defined at 95% confidence level 
(p< 0.05 was considered to be statistically significant). Fold change was calculated 
by dividing the average (mean) value of the experimental group to that of the control 
group. In all figures, error bars represent SEM, of at least 3 independent 
experiments. 
 
Results 
 
The flavonoid agathisflavone enhances generation of neurons 
The effects of agathisflavone (FAB) on the neuronal population in primary 
cortical co-cultures of neurons and glial cells were investigated by quantification of 
the number of neuronal cells after 72 h of treatment. Compared to controls, cultures 
treated with agathisflavone showed significant increases in the proportion of cells 
expressing the neuronal markers DCX (from 33% in controls to 52% in 
agathisflavone, p<0.05; Fig. 2A- C), βTubulin III (37% in controls to 58% 
agathisflavone, p<0.05; Fig. 2D- F), MAP2(40% in controls to 58% in agathisflavone, 
p<0.05; Fig 2G, H and I) and vGlut2 (36% in controls to 47% in agathisflavone, 
p<0.05; Fig 2P-R). We also observed an apparent increase in the expression of 
Neurofilament 200, although this was not quantified (Fig. 2M, N). On the other hand, 
agathisflavone had no significant effect on the percentage of Iba+ microglia (12.5% 
in control and 13% in agathisflavone, p>0.05; Fig 2F-O) or GFAP+ astrocytes (53 % 
in control and 46% in agathisflavone, p>0.05; Fig 2J-L).  
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The pro-neuronal effects of agathisflavone involve estrogen receptors 
To investigate the involvement of Estrogen receptor (ER) signaling on the 
effects of agathisflavone on neuronal and neuronal progenitor number, we carried 
out experiments with antagonists to ERα and ERβ subtypes. Antagonists were 
added to cultures 2h before and concomitant with agathisflavone treatment and the 
number of neurons was measured after 72 h. Pharmacological antagonism of ERα 
with methyl-piperidinopyrazole (MPP), a selective and widely used antagonist of this 
receptor, markedly reduced the number of βTubIII+ cells compared with 
agathisflavone-treated cultures, from 50% in agathisflavone-treated cultures to 21% 
in MPP + agathisflavone (Fig. 3B, C and E; p<0.05, unpaired t-test). Similarly, 
blocking ERβ with pyrazolo[1,5-a]pyrimidine (PHTPP) resulted in a significant 
decrease in the number of βTubIII+ cells, from 50% in agathisflavone to 32% in 
PHTPP  + agathisflavone (Fig. 3B, D and E; p<0.05, unpaired t-test).  
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Agathisflavone protects against glutamate-mediated excitotoxicity 
Excitotoxicity is a pathological event characterized by neuronal excitation 
through overstimulation of neurons by excitatory glutamate receptors contributing to 
neuronal degeneration in many acute and chronic CNS diseases. To investigate the 
neuroprotective potential of agathisflavone against glutamate-mediated 
excitotoxicity, neuron-glial co-cultures were exposed to glutamate (1mM) for 4 h and 
then treated with agathisflavone for 24h or 72h; 17β estradiol (EST) has known 
neuroprotective effects (Arevalo et al., 2015) and was used as a positive control. 
First, we used Fluoro Jade B (FJ-B) to stain neurons undergoing degeneration 
and compared the effects of different concentrations of agathisflavone (0.1-10µM) on 
glutamate-mediated excitotoxicity (Fig.4B). As expected, we observed a significant 
increase in FJ-B Fluorescence Intensity after treatment with 1mM of glutamate (0.60, 
Fig. 4B), when compared with control treated with DMSO vehicle (0.31, Fig. 4B). In 
contrast, treatment with agathisflavone after exposure to glutamate significantly 
reduced FJ-B fluorescence intensity at all concentrations of agathisflavone tested 
(0.33 agathisflavone 0.1 µM, 0.35 agathisflavone 1 µM, 0.37 agathisflavone 10 µM, 
Fig. 4B), significantly less than glutamate treated cells (0.60, Fig. 4B); similar results 
were observed in cells treated with EST after exposure to glutamate (0.42; Fig. 4B). 
The FJ-B Fluorescence Intensity was similar in the experimental groups treated with 
agathisflavone or EST alone when compared with control groups (Fig. 5B), 
suggesting that agathisflavone and EST have no effect on cell death in cortical co-
cultures in the absence of a cytotoxic insult (0.33 agathisflavone 0.1 µM, 0.27 
agathisflavone 1 µM, 0.39 agathisflavone 10 µM, 0.39 EST 0.1 µM, Fig. 4B). In 
addition, we examined whether agathisflavone (10 µM) affected glutamate-mediated 
apoptosis, using TUNEL staining, and the results indicated that agathisflavone 
decreased significantly the amount of TUNEL-positive cells (Fig. 4A). 
To evaluate whether agathisflavone was protecting specifically by reducing 
caspase 3, we also evaluated by immunofluorescence the amount of cleaved 
caspase-3 in co-culture (Fig. 4C). Cultures exposed to glutamate (Glut), showed a 
significant increase in the percentage of caspase-3+ cells (14.5% Fig. 4C and D), 
compared with controls (4.4% Fig. 4C and D). Compared to the glutamate treated 
group (14.5%), agathisflavone treatment significantly reduced the percentage of 
Caspase 3 positive cells (5.7% Fig. 4C and D), and similar results were observed in 
cells treated with EST (5.4% Fig. 4C and D); agathisflavone or EST treatment did not 
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significantly alter the proportion of Casp3+ cells in normal medium (Fig. 4C and D). 
These data show that agathisflavone protects against glutamate-mediated neuronal 
excitotoxicity. 
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Agathisflavone reduces neuroinflammation induced by glutamate 
Immunofluorescence analyses of microglia was performed in neuron-glial co-
cultures 72 h after treatment to investigate the activation of microglia after glutamate-
mediated excitotoxicity (Fig. 5A). A significant increase in the percentage of Ox42+ 
microglial cells was observed after glutamate treatment (10.1%) compared with 
controls (2.0%). In contrast, agathisflavone significantly reduced microglial activation 
induced by glutamate, as observed by the reduction in the percentage of Ox42+cells 
(3.6%), and similar results were observed following treatment with 17β Estradiol 
(4.8%). We did not observe differences in the percentage of Ox42+ cells in groups 
treated only with agathisflavone or EST (Fig. 5B). 
In order to evaluate if glutamate-mediated excitotoxicity induces distinct 
cytokine expression, qPCR was performed in neuron-glial co-cultures 24 h after 
treatments. Glutamate (Glut) induced an increase of mRNA expression of TNF (1.4), 
IL1β (2.0), IL6 (2.4), arginase1 (1.46) and IL10 (1.35), compared with control (1.0); 
however, the expression levels of TGF-β was not altered. In contrast, agathisflavone 
reduces the expression of the inflammatory cytokines TNF (1.2), IL1β (1.5), IL6 (1.4), 
induced by glutamate, whereas expression of anti-inflammatory markers arginase1 
(2.26) and IL10 (4.31) were increased by agathisflavone (Fig. 5C). EST also reduced 
the levels of TNF (1.2), IL1β (1.7), IL6 (1.3) and increased the expression of 
arginase1 (2.2) and IL10 (5.3) when compared with glutamate. Treatment with 
agathisflavone or EST alone showed increased expression of IL6 (1.2 and 1.4 
respectively) and IL10 (1.2, 1.4) but not other targets (IL1β, TNF, IL1β, arginase and 
TGF β), when compared with control group. 
To investigate the molecular mechanisms involved in the neuroprotection 
induced by agathisflavone, qPCR of neurotrophins was performed in neuron-glial co-
cultures 24 h after treatments. Glutamate induced an increase in mRNA expression 
of GDNF (1.3), but reduced the levels of BDNF (0.7), when compared with control 
(1.0); no differences were observed in the expression of NGF, NT4 and CDNF. 
Treatment with glutamate plus agathisflavone increased the levels of BDNF (2.2), 
NGF (1.7), NT4 (2.4) and GDNF (2.2), but not CDNF (1.05), when compared with 
glutamate treated cells. Similarly, treatment with EST plus glutamate elevated the 
levels of BDNF (1.5), NGF (1.4), NT4 (4.0) and GDNF (1.9), but not CDNF (1.12), 
compared to glutamate treated cells. Treatment with agathisflavone alone increased 
the expression of BDNF (1.2), NT4 (1.2, 1.4) and CDNF when compared with control 
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medium group; EST alone elevated the levels of BDNF (1.5) and GDNF (1.3) (Fig. 
5D). 
 
Fig.5. Agathisflavone reduced microglia activation induced by glutamate. (A) Representative 
immunofluorescence images staining for GFAP (green) and OX42 (red) counterstained with DAPI 
(blue) in co-cultures. (B) Bar graph showing the percentage of Ox42+cells in each treatment group. 
(C) FAB and EST modulate cytokine expression after glutamate treatment. qPCR analysis showing 
that cells treated with FAB or EST reduced expression of the pro-inflammatory cytokines TNFα, IL1β, 
and IL6, whereas there was increased expression of the anti-inflammatory markers IL10 and ARG1, 
but not TGFβ. (D) FAB modulates the expression of neurotrophins: qPCR analysis showing that cells 
treated with FAB or EST increased expression the neurotrophins BDNF, NGF, NT4 and GDNF, but 
not CDNF after glutamate induced excitotoxicity. (E) Confocal photomicrographs of isolated microglia 
cultures immunostained for the microglial marker Iba1 (green) and the M1 microglial marker CD68 
(red); nuclei were counterstained with DAPI (blue). Cells were incubated with 0.01% of vehicle 
(DMSO) or treated with 1mM Glutamate (Glu),1 µg/ mL of LPS, 20ng/mL of IL4,  10 µM of 
agathisflavone (FAB), 100nM of 17βEstradiol (EST) or  the combination of  1 mM Glu plus 10µM FAB 
(Glu + FAB) or  the combination of  1 mM Glu plus 100nM EST (Glu + EST). (F) Confocal 
photomicrographs of isolated microglia cultures, immunostained for the microglial marker Iba1 (red) 
and the M2 microglial marker CD206 (green); nuclei were counterstained with DAPI (blue).Values in 
B-D are expressed as the mean±SEM, n=3; significant differences are indicated with *P≤0.05 when 
compared with control, #P<0.05 when compared with glutamate treatment and &p<0.05 when 
compared with Glut +FAB treatment, one way ANOVA. Scale bar: 50 mm (A) and 100mm (E and F). 
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To confirm the effects of agathisflavone on the apparent change in the M1/M2 
polarization of microglial cells after glutamate-induced excitotoxicity, isolated 
microglial cultures were pre-treated with glutamate and then treated with 
agathisflavone and EST and processed for immunofluorescence for Iba1, a general 
marker for microglia, plus CD68 and CD206 for the M1 and M2 phenotypes, 
respectively. Cultures treated with 1 µg/mL of LPS were used as a positive control of 
the M1 phenotype, and cultures treated with 20 ng/mL IL4 were used as a control of 
the M2 phenotype. We observed an increase in the levels of the M1 marker CD68 in 
cells treated with LPS and EST, when compared with control, whereas 
agathisflavone and glutamate did not change the levels of CD68 in these conditions 
(Fig. 5E). In comparison, the M2 marker CD206 was increased in IL4 treated groups 
and reduced in cells treated with LPS or glutamate, when compared with control 
(Fig. 5F). Notably, agathisflavone and EST treatment alone and after pre-treatment 
with glutamate resulted in an increase in CD206 expression. Together, these results 
show that glutamate-mediated excitotoxicity induces microglial activation and that 
agathisflavone reduces inflammation induced by glutamate and polarizes microglia 
towards an M2 phenotype. 
 
Agathisflavone increases the levels of EAAT1 and GS in astrocytes 
 
Since one of the most important functions of astrocytes in the brain is their 
control of glutamate clearance, whose accumulation in the extracellular space can 
trigger excessive activation of glutamatergic receptors and lead to excitotoxicity, a 
characteristic of many neurodegenerative diseases (Murphy-Royal et al., 2017). 
Based on these observations, we postulated that astrocytes could have a role in the 
neuroprotective effects of agathisflavone. To investigate this, we performed 
immunofluorescence and western blot analysis of EAAT1 and GS expression on co-
cultures 72 h after treatments. Cultures exposed to glutamate (Glut), showed a 
decrease in the intensity EAAT1 fluorescence (7.61) compared with control groups 
(9.45, Fig. 6A and B). agathisflavone and EST treatment increased the levels of 
EAAT1 (13.52 and 13.56 respectively) when compared with control treated with the 
vehicle and when compared with glutamate treated group . Treatment with 
agathisflavone after glutamate induced excitotoxicity markedly increased the levels 
of EAAT1 (21.85), compared with control (9.45, a) and glutamate (7.61); EST also 
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elevated the levels of EAAT1 after glutamate induced excitotoxicity (17.99). 
Furthermore, EAAT1 expression was increased to a larger extent in agathisflavone 
than EST after glutamate induced excitotoxicity (Fig. 6A and B). 
 
Fig.6. Agathisflavone increases the levels of Excitatory Amino Acid Transporter 1 (EAAT1) and 
Glutamine synthetase (GS) in astrocytes. Cells were incubated with 0.01% of vehicle (DMSO) or 
treated with 1mM Glutamate (Glut), 10 µM of agathisflavone (FAB), 0.1 µM of 17βEstradiol (EST) or 
the combination of 1 mM Glut plus 10µM FAB (Glut + FAB) or the combination of 1 mM Glu plus 0.1 
µM EST (Glut + EST). (A) Representative immunofluorescence images stained for β Tubulin III 
(green) and EAAT1 (red), counterstained with DAPI (blue) in neuron-glial co-cultures. (B) Bar graph of 
the fluorescence intensity as a percentage of the total number of cells showing significantly increased 
EAAT1 staining in Glut + FAB and Glut + EST-treated cells compared to glutamate. (C) 
Representative immunofluorescence images stained for β Tubulin III (green) and GS (red), 
counterstained with DAPI (blue), in neuron-glial co-cultures. (D) Bar graph of the fluorescence 
intensity as a percentage of the total number of cells showing significantly increased GS staining in 
Glut + FAB and Glut + EST-treated cells compared to glutamate. (E) Western blot showed increased 
expression of GS in treated cells, the results were normalized relative to control group considered as 
100% and at least three independent experiments. The values are expressed as the mean±SEM; 
n=3; significant differences are indicated with *P≤0.05, ***p<0.001 when compared with control, 
#P<0.05, ###p<0.001 when compared with glutamate treatment and &p<0.05 when compared with 
Glut +FAB treatment, one way ANOVA. Scale bar: 50 µm. 
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Glutamine synthetase (GS) is an ATP-dependent enzyme found in most 
species that synthesizes glutamine from glutamate and ammonia. In the CNS, GS is 
exclusively located in astrocytes where it serves to maintain the glutamate-glutamine 
cycle (Jayakumar and Norenberg, 2016). We evaluated the levels of GS in co-
cultures by immunofluorescence and western blot. The immunofluorescence showed 
a tendency of reduction in the levels of GS in cultures exposed to glutamate (Glut, 
Fig. 6C and D), which was confirmed by western blot that showed a significantly 
decreased level of GS (23.99%), when compared with control groups (100%, Fig. 
6E). The treatment with agathisflavone alone did not change significantly the levels 
of GS (84%, Fig. 6E), whereas agathisflavone after glutamate induced excitotoxicity 
resulted in an increase of the levels of GS showed by immunofluorescence and 
confirmed by western blot (87% Fig. 6E) when compared with glutamate (23.99%); 
the results of agathisflavone after glutamate induced excitotoxicity was similar to 
control levels. Western blot showed that treatment with EST alone reduced the levels 
of GS (65.9%, Fig. 6E), when compared with the control (100%, Fig. 6E), but 
increased the level of EAAT1 after glutamate induced excitotoxicity (70.5%), when 
compared with glutamate (23.99%). These data show that agathisflavone modulates 
the astrocyte response against glutamate-mediated excitotoxicity. 
 
 
Discussion 
Glutamate-mediated excitotoxicity is a major factor in neuronal loss in 
neurodegenerative diseases. Notably, there is evidence that estrogens are 
neuroprotective, but their therapeutic use in humans is limited by the increased risk 
of cancer. Here, we provide evidence that the flavonoid agathisflavone acts as a 
modulator of estrogen receptors (ER) to promote the generation of neurons in vitro 
and protects against glutamate-mediated neurotoxicity as effectively as the synthetic 
estrogen estradiol. In neuron-glial co-cultures, we show that the protective effects of 
agathisflavone again glutamate-mediated neurotoxicity are mediated at least in part 
by polarizing microglia towards an anti-inflammatory M2 phenotype and increased 
expression of neuroprotective trophic factors. In addition, agathisflavone treatment 
maintained the expression of the glutamate regulatory proteins EAAT1 and GS in 
astrocytes, which is likely to be important in protecting neurons against elevated 
levels of glutamate. The neuroprotective and anti-inflammatory potency of 
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agathisflavone suggest it may provide a potential alternative to estrogens for the 
treatment of neurodegeneration.  
 
The increased neuronal population in cortical cultures after agathisflavone 
treatment gave rise to the population of doublecortin-(DCX)-expressing cells that 
comprises the late intermediate progenitor cells as well as immature neurons. 
Agathisflavone also increased the population of neurons (βTubIII + and MAP2+ Cells). 
This effect was dependent, at least partly, on estrogen receptor (ER) activation, 
since ER antagonists were capable of reducing the generation of these cells. Natural 
compounds and their potential effect on brain plasticity have become particularly 
interesting for their beneficial effects to both the general public and scientists (Ortiz-
Lopez et al., 2016). Preclinical studies, in vitro and in vivo suggest that natural 
compounds such as polyphenols modulate neuroplasticity (Dias et al., 2012). 
Several natural compounds reportedly favored the generation of new neurons (Dias 
et al., 2012). For example, epigallo-catechin-3-gallate (EGCG), a polyphenol 
compound mainly found in green tea leaves (Camellia sinensis) increased the 
population of doublecortin-(DCX)-expressing cells and also significantly increased 
net neurogenesis in the adult hippocampus (Ortiz-Lopez et al., 2016). On the other 
hand, some flavonoids, in particular apigenin, have been shown to activate estrogen 
receptors (Mak et al., 2006), which affect the development, maturation, function, and 
plasticity of the nervous system. Furthermore, it has been previously shown that the 
flavonoid apigenin induces neural differentiation of human pluripotent stem cells and 
this neural conversion was dependent, at least partly, on ER activation (Souza et al., 
2015). We previously demonstrated that agathisflavone, a product of the oxidative 
coupling of an apigenin dimer, enhances neural differentiation induced by retinoic 
acid (RA) in murine pluripotent stem cells by increasing the expression of all trans 
retinoic acid (RA) receptors (RAR) (Paulsen et al., 2011). The results of the present 
study show that agathisflavone also modulates ER signaling to promote the 
generation of neurons in vitro. 
The influence of the agathisflavone on cell death induced by glutamate has 
not been explored in co-culture previously. Glutamate is one of the most abundant 
excitatory neurotransmitters in the CNS and is particularly involved in the cortical and 
hippocampal regions, which deal especially with synaptic plasticity, memory and 
learning among other functions (Collingridge and Lester, 1989, Esposito et al., 
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2013). Excess levels of glutamate and other excitatory molecules results in over 
excitation of the ionotropic glutamatergic receptors N-methyl-d-aspartate (NMDA) 
and 2-amino-3- (3-hydroxy-5-methylisoxazol-4-yl) propionate (AMPA), and the 
release of other excitotoxins followed by excessive calcium levels in cytosol (Essa et 
al., 2013). Excitotoxicity describes the pathological event characterized by neuronal 
excitation through overstimulation of neurons by excitatory amino acids receptors of 
glutamate and aspartate (Olney, 1969). Glutamate induced excitotoxicity is 
considered a direct cause of cell degeneration in several neurological disorders, 
such as HD (Douaud et al., 2009, Malkki, 2016), PD (Rodriguez et al., 1998, Marti et 
al., 2000) and AD (Bezprozvanny and Mattson, 2008, Zhang et al., 2016). Here, we 
demonstrate that the flavonoid agathisflavone reduced neuronal cell death induced 
by glutamate excitotoxicity in neuron-glial co-cultures. The reduction of 
neurodegeneration by agathisflavone is consistent with previous results that show 
that flavonoids can reduce cell death (Zong et al., 2016, Cong et al., 2016). Our 
results show that agathisflavone reduced the percentage of cells expressing caspase 
3, a member of the caspase family of proteases that play a pivotal role in apoptosis. 
In healthy cells, caspase-3 is present in the cytoplasm as an inactive proenzyme, 
pro-caspase-3. During apoptosis, pro-caspase-3 is hydrolyzed to the active-caspase-
3 (D'Amelio et al., 2011). 
Flavonoids are widely known as antioxidants and the mechanisms by which 
they protect against cell death induced by glutamate are likely to be multifarious. 
Recently, much interest has focused on the suggested anti-inflammatory and 
neuroprotective effects of dietary derived polyphenols (Vauzour et al., 2015). We 
demonstrated that the flavonoid agathisflavone (bis-apigenin) reduces the 
neuroinflammation induced by glutamate, by modulating microglial activation and 
reducing the expression of pro-inflammatory cytokines TNF, IL6 and IL1β, and 
increasing the expression of anti-inflammatory markers. The anti-inflammatory 
effects of flavonoids are well established (Rahimifard et al., 2017). For example, in 
an in vivo model, apigenin showed a significant reduction in severity of experimental 
autoimmune encephalomyelitis (EAE) progression and in relapses observed in 
C57BL/6 (progressive) and SJL/J (relapse-remitting) mouse models of MS, where 
apigenin modulated microglial activation via inhibition of STAT1-induced CD40 
expression (Rezai-Zadeh et al., 2008). In addition, a recent study using the human 
induced pluripotent stem cell (hiPSC) model of familial and sporadic AD to assess 
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the neuroprotective activity of apigenin, demonstrated that hiPSC-derived AD 
neurons exhibited a hyper-excitable calcium signalling phenotype, elevated levels of 
nitrite, increased apoptosis, reduced neurite length and increased susceptibility to 
inflammatory stress challenge from activated murine microglia, in comparison to 
neurons derived from healthy controls.  In this study, they identified that the flavonoid 
apigenin had potent anti-inflammatory effects with the ability to protect neurites and 
cell viability by promoting a down-regulation of cytokine and nitric oxide (NO) release 
in inflammatory cells (Balez et al., 2016). 
Neurotrophins (NTFs) are endogenous peptides secreted from neurons and 
glial cells, and are associated with regulating brain function, survival, and 
development of individual cells and neuronal networks across the entire brain. 
Specifically, NTFs regulate synaptic plasticity, protect neurons from apoptosis, and 
stimulate neurogenesis (Skaper, 2012, Leal et al., 2015, Kuipers et al., 2016, 
Wurzelmann et al., 2017). The neuroprotective effect of agathisflavone was 
associated with the increase of the NTFs BDNF, NGF, CDNG, NT4 and GDNF. 
Survival signaling is important to suppress apoptosis and counterbalance death 
signaling in the nervous system. Several studies have shown that polyphenolic 
compounds enhance neuronal survival and increase the expression levels of NTFs 
(Moosavi et al., 2016). For example, apigenin reverses depression-like behavior 
induced by chronic corticosterone treatment in mice. In addition, the administration of 
apigenin ameliorated the levels of BDNF in corticosterone-treated mice. The 
antidepressant-like effects of apigenin have been suggested to be mediated, at least 
partly, by up-regulation of BDNF levels in the hippocampus (Weng et al., 2016). 
BDNF, the main neurotrophin expressing in the central nervous system, has an 
important role in promoting survive, growth and synaptic plasticity in the CNS (Huang 
and Reichardt, 2001). 
Astrocytes, earlier presumed to serve as supportive roles for the neuronal 
network, have recently been shown to play an active role in the synaptic dysfunction, 
impairment of homeostasis, inflammation, as well as excitotoxicity in relation to 
several neurological disorders (Dezsi et al., 2015). The role of astrocytes in the 
neuroprotective effects of agathisflavone against glutamate-induced excitotoxicity 
was evaluated. In physiological conditions to prevent over-stimulation, glutamate is 
removed from the synaptic cleft by astrocytes trough EAAT located in the plasma 
membrane and converted through the action of GS to L-glutamine, which is released 
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to the extracellular fluid and taken up by neurons (Danbolt, 2001, Hazell et al., 2001, 
Walton and Dodd, 2007). We demonstrated that treatment with agathisflavone after 
excitotoxicity induced by glutamate increased the levels of EAAT1 and GS in 
astrocytes, suggesting that an important neuroprotective effect of agathisflavone is 
via glutamate uptake and recycling in astrocytes. 
In conclusion, we showed that treatment of co-cultures of neurons and glial 
cells with agathisflavone increases the neuronal population at least in part via ER. 
Furthermore, we demonstrate that agathisflavone has broad neuroprotective effects 
against glutamate induced excitotoxicity, associated with anti-inflammatory effects on 
microglia and increased expression of neuroprotective cytokines and trophic factors. 
Taken together, these data suggest that agathisflavone could be a potential agent for 
treatment of excitotoxicity-related diseases. 
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